Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 20 de 325
Filtrar
1.
BMC Infect Dis ; 24(1): 1036, 2024 Sep 27.
Artículo en Inglés | MEDLINE | ID: mdl-39333883

RESUMEN

We report the case of a young woman sough care for disseminated form of Yersinia enterocolitica infection (pseudoappendicitis with mesenteric lymph node, arthralgia, glomerulonephritis and hepatitis) diagnosed on Western Blot method for the detection of Yersinia antibodies. The patient also presented a rare concomitant cutaneous manifestation, as Sweet's syndrome, confirmed histologically. Neutrophilic dermatosis is an exceptional skin features among post-infectious autoimmune disorders when encountering Yersinia enterocolitica infection in clinical practice.


Asunto(s)
Síndrome de Sweet , Yersiniosis , Yersinia enterocolitica , Humanos , Yersinia enterocolitica/aislamiento & purificación , Femenino , Yersiniosis/complicaciones , Yersiniosis/microbiología , Síndrome de Sweet/tratamiento farmacológico , Síndrome de Sweet/patología , Síndrome de Sweet/diagnóstico , Adulto , Anticuerpos Antibacterianos/sangre
2.
Dermatology ; 240(4): 659-664, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38810613

RESUMEN

INTRODUCTION: Neutrophilic dermatoses (NDs) often occur secondary to inflammatory conditions, medication exposure, and hematologic malignancy. While malignancy-associated NDs (MA-NDs) have been well reported among those with hematologic cancers, little is known about drug-induced NDs (DI-NDs) within this population. The objective of this study was to compare the presentations and outcomes of patients with hematologic malignancies who developed MA-NDs and DI-NDs. METHODS: Cases of ND occurring between 2013 and 2023 among those with hematologic malignancies were identified from the electronic medical records of our institution. Patient characteristics, recent medication exposures, cancer mutations, and disease outcomes were reviewed. Patients were categorized with DI-ND if they were recently exposed to one of four medications known to be commonly associated with ND or were otherwise categorized with MA-ND. We report a descriptive analysis of cases of DI-ND and MA-ND. RESULTS: We identified 52 patients with ND and co-occurring hematologic malignancy including 16 cases of DI-ND (30.8%) and 36 cases of MA-ND (69.2%). The most common ND in both groups was Sweet's syndrome. Chronic underlying conditions including solid tumors, inflammatory disorders, chronic viral infection, and tobacco use were more common among those with MA-ND. Among those with DI-ND, tyrosine kinase inhibitors were the most commonly associated drugs (43.8%). The most common cancer mutation among those with DI-ND was FLT3 (43.8%), while the most common mutation among those with MA-ND was TP-53 (19.4%). Among those who had died at the time of data collection, 90.0% of those with DI-ND and 66.7% of those with MA-ND died within 1 year of ND diagnosis. CONCLUSION: Most cases of ND occurring with hematologic malignancies develop secondary to cancer rather than drug exposure. Different cancer mutations may predispose to DI-ND and MA-ND. Further research is needed to establish diagnostic criteria for DI-ND and to determine the pathogenic role of specific cancer mutations, particularly FLT3, in the development of ND.


Asunto(s)
Neoplasias Hematológicas , Síndrome de Sweet , Humanos , Neoplasias Hematológicas/complicaciones , Femenino , Masculino , Persona de Mediana Edad , Anciano , Síndrome de Sweet/epidemiología , Estudios Retrospectivos , Adulto , Anciano de 80 o más Años , Erupciones por Medicamentos/etiología , Erupciones por Medicamentos/epidemiología , Neutrófilos , Antineoplásicos/efectos adversos
3.
Pediatr Dermatol ; 2024 Jun 17.
Artículo en Inglés | MEDLINE | ID: mdl-38886158

RESUMEN

An otherwise healthy 4-week-old term female of Japanese heritage presented with a 1-week history of asymptomatic progressive, generalized skin lesions. The lesion morphology, distribution, and dermatopathology result was consistent with Sweet syndrome. The patient was found to have a congenital type H rectovestibular fistula. This case highlights the rare association of rectovestibular fistula in neonatal Sweet syndrome which has only been described in neonates of Japanese heritage.

4.
Pediatr Dermatol ; 2024 Jun 11.
Artículo en Inglés | MEDLINE | ID: mdl-38863220

RESUMEN

A 14-month-old girl with very early-onset inflammatory bowel disease (VEO-IBD) was admitted with a flare of her bowel disease and subsequently developed high fevers, joint pain, and skin lesions during her hospitalization. Workup demonstrated bowel-associated dermatosis-arthritis syndrome in the setting of VEO-IBD, a neutrophilic dermatosis rarely reported in children that can be challenging to diagnose and treat, with limited literature for patients under 2 years of age.

5.
Rev Med Liege ; 79(7-8): 521-526, 2024 Jul.
Artículo en Francés | MEDLINE | ID: mdl-39129552

RESUMEN

Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis. Half of the cases are associated with an immune dysfunction and are frequently triggered by pathergy such as a tissular aggression via surgery or burn wounds. A patient with ulcerative colitis presented a PG at the site of an iontophoresis patch for tendinopathy. Treatment in a specialized burn center, corticosteroid therapy and adapted local care contributed to a favourable evolution. PG remains a diagnosis of exclusion and inflammatory phenomena must be differentiated from infectious causes such as necrotizing fasciitis to initiate immunosuppressive treatment. Being rare and difficult to diagnose and to treat as well as associated with potentially severe sequelae, a multidisciplinary team is required for the management of PG.


Le Pyoderma gangrenosum (PG) est une dermatose neutrophilique rare. Il est, dans la moitié des cas, associé à une maladie dysimmunitaire et il est fréquemment déclenché par un phénomène de pathergie, défini comme une agression tissulaire par une intervention chirurgicale ou encore une brûlure. Une patiente avec une rectocolite ulcéro-hémorragique a développé un PG sur le site d'application d'un patch d'ionophorèse pour une tendinopathie. Un traitement par une corticothérapie, un traitement immunosuppresseur local et des soins locaux adaptés ont permis une évolution favorable. Le PG reste un diagnostic d'exclusion et les phénomènes inflammatoires doivent être différenciés de phénomènes infectieux, comme la fasciite nécrosante, afin d'initier rapidement des immunosuppresseurs. Comme il s'agit d'une pathologie rare avec un diagnostic difficile, que des séquelles peuvent être catastrophiques et qu'un traitement immunosuppresseur complexe doit être instauré, une équipe pluridisciplinaire est requise pour la prise en charge de cette pathologie.


Asunto(s)
Tratamiento Conservador , Piodermia Gangrenosa , Humanos , Piodermia Gangrenosa/etiología , Piodermia Gangrenosa/diagnóstico , Piodermia Gangrenosa/terapia , Colitis Ulcerosa/complicaciones , Colitis Ulcerosa/terapia , Femenino , Persona de Mediana Edad , Tendinopatía/terapia , Tendinopatía/etiología , Tendinopatía/diagnóstico , Masculino
6.
Ter Arkh ; 96(6): 622-627, 2024 Jul 07.
Artículo en Ruso | MEDLINE | ID: mdl-39106504

RESUMEN

This clinical case series presents descriptions of 3 patients with familial Mediterranean fever (FMF) who have atypical manifestations and abnormal inheritance mechanisms in terms of Gregor Mendel's laws. Although molecular genetic testing can help with disease diagnosis, it is not always conclusive. The primary need for genetic testing in atypical cases is to explain the mechanism of inflammation and to select the optimal therapy. These clinical observations demonstrate the changes in the spectrum of phenotypic manifestations of FMF in the context of the widespread introduction of molecular genetic methods.


Asunto(s)
Fiebre Mediterránea Familiar , Humanos , Fiebre Mediterránea Familiar/diagnóstico , Fiebre Mediterránea Familiar/genética , Masculino , Femenino , Adulto , Pruebas Genéticas/métodos , Colchicina/uso terapéutico , Pirina/genética , Diagnóstico Diferencial
7.
J Am Acad Dermatol ; 88(6): 1338-1344, 2023 06.
Artículo en Inglés | MEDLINE | ID: mdl-31499154

RESUMEN

Neutrophilic dermatosis of the dorsal hands (NDDH) is an uncommon localized variant of Sweet syndrome first described in 1995. It is characterized by tender erythematous plaques, pustules, and bullae on the dorsa of the hands. A total of 123 cases of NDDH are included in this review. The mean patient age was 62.1 years, and there was a slight female preponderance. Overall, 78.0% of cases had bilateral involvement, and other sites were affected in almost a third of cases. Underlying disease was found in ∼40% of patients, with the most common associations being hematologic disorders (gammopathies, myelodysplasias, or malignancies), recent infection, solid organ tumors, and inflammatory bowel disease. Systemic or topical corticosteroids or both were employed in the treatment of 88.1% of cases, while dapsone, colchicine, and tetracyclines were the most common steroid-sparing agents used. Improvement was often rapid and complete resolution the norm. Although uncommon, NDDH is frequently misdiagnosed, and thus, its exact prevalence is probably underestimated. Misdiagnosis might have significant implications, including treatment delays or incorrect management. Moreover, recognition of NDDH is important, since a correct diagnosis should trigger a search for underlying diseases and proper treatment with corticosteroids, steroid-sparing agents, or both, which is almost invariably curative.


Asunto(s)
Dermatitis , Dermatosis de la Mano , Síndrome de Sweet , Humanos , Femenino , Persona de Mediana Edad , Dermatosis de la Mano/diagnóstico , Dermatosis de la Mano/tratamiento farmacológico , Dermatosis de la Mano/complicaciones , Glucocorticoides , Síndrome de Sweet/diagnóstico , Síndrome de Sweet/tratamiento farmacológico , Síndrome de Sweet/complicaciones , Antibacterianos , Dermatitis/complicaciones , Vesícula
8.
J Am Acad Dermatol ; 89(6): 1209-1214, 2023 12.
Artículo en Inglés | MEDLINE | ID: mdl-35121074

RESUMEN

In 2020, Beck et al1 described a novel adult autoinflammatory syndrome entitled VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic), a newly-discovered disorder that connected previously unrelated inflammatory syndromes and a prototype for a new class of hematoinflammatory diseases.2 Eighty-nine percent of published cases have documented skin involvement, but despite the high incidence and diagnostic accessibility of skin manifestations, there has been little focus on the dermatological features of VEXAS syndrome thus far. A PubMed search of all published case reports of VEXAS syndrome to date was performed, with inclusion of all cases confirmed by genetic sequencing, and this review summarizes the reported dermatological signs. There have already been 141 confirmed published cases since original publication, 126 of which had documented cutaneous signs.1-34 A wide range of skin presentations are reported, including Sweet-like urticated and tender erythematous nodules, cartilaginous involvement with chondritis, cutaneous vasculitis, and periorbital angiodema.1-34 Many patients had been diagnosed with Sweet syndrome, relapsing polychondritis, polyarteritis nodosa, or erythema nodosum.1-34 Hallmarks of skin histopathology are a neutrophilic dermatosis with coexisting or exclusive leukocytoclastic vasculitis.1 The new classification therefore helps link previously disparate inflammatory skin conditions into a unifying pathophysiological pathway.


Asunto(s)
Dermatitis , Vacuolas , Adulto , Humanos , Dermatólogos , Piel , Dermatitis/diagnóstico , Mutación
9.
J Cutan Pathol ; 50(1): 29-34, 2023 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-35950337

RESUMEN

Iododerma is an uncommon dermatosis caused by excessive iodine exposure and is associated with significant morbidity and mortality. Because of its heterogenous clinical presentation and variable histopathological findings, which depend on the time the skin biopsy is performed, the diagnosis of iododerma is often delayed. We report a rare case of acute iododerma in a woman with end-stage diabetic nephropathy with antecedent radioiodine contrast exposure, presenting histopathologically as cryptococcoid neutrophilic dermatosis (CND). We underscore important clinicopathological pitfalls to avoid misdiagnosis with similar overlapping entities such as Sweet syndrome, review all published cases of CND and draw novel insights into its associated entities.


Asunto(s)
Dermatitis , Erupciones por Medicamentos , Síndrome de Sweet , Femenino , Humanos , Radioisótopos de Yodo , Dermatitis/patología , Piel/patología , Síndrome de Sweet/inducido químicamente , Síndrome de Sweet/diagnóstico , Erupciones por Medicamentos/patología
10.
J Cutan Pathol ; 50(6): 524-529, 2023 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-36617531

RESUMEN

Histopathologic findings in neonatal lupus erythematosus (NLE) are usually congruent with those of subacute cutaneous lupus erythematosus. However, neutrophilic dermatosis-type histopathologic features are being increasingly recognized in the literature including rare cases with variant histiocytoid morphology. We report the case of a 7-week-old male presenting with figurate erythema. His mother was found to have elevated anti-nuclear antibodies and was positive for anti-SSA/Ro, anti-SSB/La antibodies and Ro52 autoantibodies. The infant had a similar serological profile. Skin biopsy showed a histiocytoid interstitial infiltrate with mild lichenoid features, sparse neutrophils and mild leukocytoclasis. The histiocytoid infiltrate showed prominent CD68, CD163, and myeloperoxidase expression. Isolated clusters of CD123+ histiocytes were also present. This case highlights the rare finding of non-bullous neutrophilic dermatosis with histiocytoid change in neonatal lupus. In neonates presenting with figurate erythemas with morphological histiocytic change on biopsy, NLE should be considered as a differential diagnosis and investigated for accordingly.


Asunto(s)
Dermatitis , Lupus Eritematoso Cutáneo , Lupus Eritematoso Sistémico , Lactante , Recién Nacido , Humanos , Masculino , Eritema/patología , Dermatitis/patología , Lupus Eritematoso Sistémico/patología , Lupus Eritematoso Cutáneo/patología , Anticuerpos Antinucleares
11.
J Cutan Pathol ; 50(10): 884-889, 2023 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-37403191

RESUMEN

Fixed drug eruption (FDE) is an adverse drug reaction characterized by recurrent circumscribed lesions at the same location upon re-exposure to the culprit medication, resulting in distinct postinflammatory hyperpigmentation. Histopathologically, FDE demonstrates a predominantly lymphocytic interface or lichenoid infiltrate with basal cell vacuolar changes and keratinocyte dyskeratosis/apoptosis. The term "neutrophilic fixed drug eruption" has been used to describe cases in which the inflammatory infiltrate is predominantly neutrophilic. The infiltrate can extend deeper in the dermis, potentially mimicking a neutrophilic dermatosis such as Sweet syndrome. We present two cases and review the literature to discuss the possibility that a neutrophilic inflammatory infiltrate may be an expected finding in FDE, rather than a histopathologic variant.


Asunto(s)
Dermatitis , Erupciones por Medicamentos , Hiperpigmentación , Síndrome de Sweet , Humanos , Erupciones por Medicamentos/etiología , Erupciones por Medicamentos/patología , Síndrome de Sweet/inducido químicamente , Síndrome de Sweet/diagnóstico , Síndrome de Sweet/tratamiento farmacológico , Hiperpigmentación/inducido químicamente
12.
Pediatr Dermatol ; 40(6): 1086-1090, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37002583

RESUMEN

Pyoderma gangrenosum is a rare neutrophilic dermatosis characterized by painful skin ulcers with necrotic, undermined margins. In severe cases, particularly in pediatric patients, work-up for an associated autoimmune, inflammatory, malignant, or genetic disorder should be considered based on the clinical presentation. We report a unique case of pediatric pyoderma gangrenosum with a leukemoid reaction, secondary to an autosomal recessive leukocyte adhesion deficiency type 1.


Asunto(s)
Reacción Leucemoide , Síndrome de Deficiencia de Adhesión del Leucocito , Piodermia Gangrenosa , Úlcera Cutánea , Humanos , Niño , Piodermia Gangrenosa/complicaciones , Piodermia Gangrenosa/diagnóstico , Síndrome de Deficiencia de Adhesión del Leucocito/complicaciones , Síndrome de Deficiencia de Adhesión del Leucocito/diagnóstico , Síndrome de Deficiencia de Adhesión del Leucocito/genética , Reacción Leucemoide/complicaciones
13.
Pediatr Dermatol ; 40(1): 207-209, 2023 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-36373208

RESUMEN

Sweet syndrome (SS), also called acute febrile neutrophilic dermatosis, is rare in the pediatric population, especially in infants and neonates. We present a case of infantile SS that developed 1 day after the MMRV vaccine; we suggest a possible causal relationship between the MMRV vaccine and SS.


Asunto(s)
Síndrome de Sweet , Lactante , Recién Nacido , Humanos , Niño , Síndrome de Sweet/etiología , Vacuna contra el Sarampión-Parotiditis-Rubéola , Vacuna contra la Varicela , Vacunas Combinadas
14.
Postepy Dermatol Alergol ; 40(3): 355-361, 2023 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-37545820

RESUMEN

Bowel-associated dermatosis-arthritis syndrome is a neutrophilic dermatosis presenting with flu-like symptoms, arthritis and skin lesions. The type of skin presentation varies although typically consists of red patches progressing into papulopustular-type lesions. Initially, the pathogenesis of the disease was linked exclusively to bariatric surgery, but more recent reports indicate the role of gastrointestinal diseases resulting in bacterial overgrowth and consequent translocation of bacteria into the bloodstream. The disease may resolve spontaneously, however sometimes requires a treatment aimed at managing inflammation and excessive bacterial overgrowth, and therefore antibiotic therapy, immunosuppressive drugs, biological treatment and sometimes intestinal surgeries are applied.

15.
Exp Dermatol ; 31(4): 498-515, 2022 04.
Artículo en Inglés | MEDLINE | ID: mdl-35114021

RESUMEN

Pyoderma gangrenosum is a painful recurrent ulcerative neutrophilic dermatosis in which the pathogenesis is incompletely defined. Current evidence suggests that PG is associated with dysregulation of components of both the innate and adaptive immune system with dysregulation of neutrophil function and contribution of the Th17 immune axis. PG can be present in numerous heterogeneous clinical presentations and be associated with multiple inflammatory conditions including rheumatoid arthritis, inflammatory bowel disease and hidradenitis suppurativa. However, no critical evaluation of the observed molecular characteristics in PG studies in association with their clinical findings has been assessed. Additionally, emerging evidence suggests a potential role for other cell types and immune pathways including B cells, macrophages, autoantibodies and the complement system in PG, although these have not yet been integrated into the pathogenesis of disease. This systematic review aims to critically evaluate the current molecular observations regarding the pathogenesis of PG and discuss associations with clinical characteristics as well as the evidence supporting novel cell types and immune pathways in PG.


Asunto(s)
Dermatitis , Hidradenitis Supurativa , Enfermedades Inflamatorias del Intestino , Piodermia Gangrenosa , Dermatitis/metabolismo , Humanos , Neutrófilos/metabolismo , Piodermia Gangrenosa/etiología , Piodermia Gangrenosa/metabolismo
16.
Arch Biochem Biophys ; 721: 109189, 2022 05 30.
Artículo en Inglés | MEDLINE | ID: mdl-35307366

RESUMEN

Protein tyrosine phosphatase non-receptor type 6 (PTPN6) is a key regulatory protein in cellular signal transduction in the control of inflammation and cell death. Impairment of PTPN6 is known to be associated with human inflammatory diseases including neutrophilic dermatosis; however, comprehensive studies of PTPN6-associated neutrophilic dermatosis have not clearly identified the relationships involved. Reports from in vitro and in vivo studies revealed that inflammatory cytokines have increased in the white blood cells from PTPN6-knocked out mice, and systemic inflammation was also increased in these mice, resulting in skin inflammation in this model. Reports of PTPN6 regulatory functions through five pathophysiological mechanisms are summarized and discussed here including inhibition of myeloid differentiation primary response 88, enhancement of the regulatory function of receptor-interacting protein kinase, inhibition of receptor-interacting serine/threonine-protein kinase 3/mixed lineage kinase domain-like protein-dependent necroptosis, inhibition of caspase-8-dependent apoptosis, and inhibition of p38/mitogen-activated protein kinase. Treatments by blocking the pathways involved in signal transduction and inflammatory cytokine release are also summarized. Understanding this underlying mechanism could improve therapeutic strategies for neutrophilic dermatosis.


Asunto(s)
Inflamación , Proteína Tirosina Fosfatasa no Receptora Tipo 6 , Enfermedades de la Piel , Animales , Humanos , Inflamación/metabolismo , Ratones , Proteína Tirosina Fosfatasa no Receptora Tipo 6/metabolismo , Transducción de Señal
17.
Dermatol Ther ; 35(12): e15923, 2022 12.
Artículo en Inglés | MEDLINE | ID: mdl-36219526

RESUMEN

The aim of this article is to present the case of acute febrile neutrophilic dermatosis (Sweet syndrome-SS) after Ad26.COV2.S vaccination against SARS-CoV-2. To the best of our knowledge, this is the second case of SS provoked by this specific vaccine. What is more, the mildly symptomatic beginning of the disease, later followed by typical SS manifestation with a variety of symptoms including nodular erythema of the feet and oral ulcerations, made it very challenging to establish the diagnosis. The article focuses on the current literature on the acute febrile neutrophilic dermatosis, along with the coexistence with other neutrophilic dermatoses and anti-SARS-CoV-2 vaccinations as provoking factors. It emphasizes the necessity for sharing the knowledge and experience on the subject of SS's clinical manifestations and underlying causes to facilitate prompt diagnosis and introduction of appropriate treatment.


Asunto(s)
Vacunas contra la COVID-19 , COVID-19 , Úlceras Bucales , Síndrome de Sweet , Humanos , Ad26COVS1 , COVID-19/prevención & control , Úlceras Bucales/diagnóstico , Úlceras Bucales/etiología , SARS-CoV-2 , Síndrome de Sweet/diagnóstico , Síndrome de Sweet/etiología , Vacunación/efectos adversos , Vacunas contra la COVID-19/efectos adversos
18.
Mycoses ; 65(10): 918-925, 2022 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-35876217

RESUMEN

BACKGROUND: Acute Generalised Exanthematous Pustulosis (AGEP) is a rash with multiple sterile intraepidermal or subcorneal non-follicular pustules on edematous papules, with a sudden development and rapid evolution, triggered by drugs, vaccination, insect bites, exposure to mercury, and allergens. OBJECTIVES AND METHODS: We describe a female patient who developed extensive and abnormally prolonged AGEP following exposure to terbinafine and SARS-CoV vaccine. A detailed review of terbinafine-induced-AGEP cases was performed, with the aim of evaluating if the AGEP criteria would follow a different pattern when the disease is triggered by this drug. A PubMed search helped retrieve all terbinafine-induced AGEP case reports. AGEP-specific Sideroff criteria were analysed in terbinafine-induced cases and compared to other trigger causes. CONCLUSIONS: When the AGEP causative drug was terbinafine, a delay in recovery was observed, compared to the existing AGEP criteria when other causes are considered. Terbinafine frequently leads to delayed resolution AGEP probably due to the presence of the drug in the skin for several weeks after exposure, even after discontinuation, and the disease severity may be potentialised by additional factors such as concomitant viral infections or vaccination.


Asunto(s)
Pustulosis Exantematosa Generalizada Aguda , Mercurio , Pustulosis Exantematosa Generalizada Aguda/etiología , Femenino , Humanos , Piel , Terbinafina/efectos adversos
19.
Rheumatology (Oxford) ; 60(11): 5436-5446, 2021 11 03.
Artículo en Inglés | MEDLINE | ID: mdl-33693560

RESUMEN

OBJECTIVE: In 2016 specific heterozygous gain-of-function mutations in the Mediterranean fever gene MEFV were reported as causal for a distinct autoinflammatory disease coined pyrin-associated autoinflammation with neutrophilic dermatosis (PAAND). We sought to provide an extended report on clinical manifestations in PAAND patients to date and evaluate the efficacy and safety of treatment with the IL-1-blocking agent anakinra. METHODS: We undertook an open-label pilot study with anakinra. Three patients were recruited in a preliminary phase of the study with the intention to expand the treatment cohort in case of a favourable response. Acute-phase reactants and plasma cytokine levels were monitored throughout. Skin biopsies at baseline and at week 12 were stained for relevant cytokines. Available clinical data on treatment responses were retrospectively collected on additional patients. RESULTS: The three patients from the preliminary phase of the study [patients 1-3 (P1-P3)] demonstrated one failed and two partial treatment responses, where one patient opted to continue treatment with anakinra and the other favoured adalimumab. While a partial systemic response was observed, there was no appreciable effect of anakinra on the prominent cutaneous manifestations, reflected in residual local inflammatory cytokine expression in lesional skin. These observations did not warrant further expansion of the treatment cohort. Clinical data was retrospectively collected on an additional eight patients (P4-P11), highlighting both dominant and recessive inheritance with variable penetrance in PAAND and common gastrointestinal involvement that was not previously appreciated. CONCLUSION: In our experience, while anakinra appears safe, it was not superior to biologicals targeting TNF-α in PAAND despite evidence directly implicating dysregulated IL-1ß signalling.


Asunto(s)
Antirreumáticos/uso terapéutico , Enfermedades Autoinflamatorias Hereditarias/tratamiento farmacológico , Proteína Antagonista del Receptor de Interleucina 1/uso terapéutico , Trastornos Leucocíticos/congénito , Enfermedades Cutáneas Genéticas/tratamiento farmacológico , Anciano , Estudios de Casos y Controles , Femenino , Humanos , Trastornos Leucocíticos/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Fenotipo , Proyectos Piloto , Pirina/genética
20.
J Cutan Pathol ; 48(9): 1189-1192, 2021 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-33982315

RESUMEN

Sweet syndrome (SS), also known as acute febrile neutrophilic dermatosis, is an uncommon skin eruption characterized by fever, leukocytosis, and tender erythematous papules, nodules, and plaques. Histopathologically, SS lesions are characterized by marked superficial papillary edema with a dense neutrophilic infiltrate. SS is known to demonstrate both the Koebner phenomenon and pathergy. The majority of reported cases of these phenomena occur following significant cutaneous injury (e.g., biopsies, burns) rather than minor trauma such as pressure and friction. Here, we present the first known reported case of SS koebnerization secondary to minor grooming-related hair plucking. In addition, this is also the first reported case to our knowledge of SS with perifollicular involvement on histopathology.


Asunto(s)
Folículo Piloso/patología , Enfermedades de la Piel/patología , Síndrome de Sweet/diagnóstico , Síndrome de Sweet/tratamiento farmacológico , Administración Oral , Cuidados Posteriores , Biopsia con Aguja/métodos , Mentón/patología , Cara/patología , Femenino , Glucocorticoides/administración & dosificación , Glucocorticoides/uso terapéutico , Humanos , Persona de Mediana Edad , Cuello/patología , Prednisona/administración & dosificación , Prednisona/uso terapéutico , Síndrome de Sweet/patología , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda